S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
Log in
NASDAQ:TLSA

Tiziana Life Sciences Stock Forecast, Price & News

$4.30
-0.43 (-9.09 %)
(As of 01/21/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.00
Now: $4.30
$4.45
50-Day Range
$1.86
MA: $2.46
$4.73
52-Week Range
$0.62
Now: $4.30
$12.17
Volume3.13 million shs
Average Volume2.82 million shs
Market Capitalization$276.15 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.

MarketRank

Overall MarketRank

1.16 out of 5 stars

Medical Sector

860th out of 1,926 stocks

Pharmaceutical Preparations Industry

426th out of 773 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLSA
CUSIPN/A
CIKN/A
Phone44-20-7495-2379
Employees8

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($0.09) per share

Profitability

Miscellaneous

Market Cap$276.15 million
Next Earnings Date6/16/2021 (Estimated)
OptionableNot Optionable
$4.30
-0.43 (-9.09 %)
(As of 01/21/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TLSA News and Ratings via Email

Sign-up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tiziana Life Sciences (NASDAQ:TLSA) Frequently Asked Questions

How has Tiziana Life Sciences' stock price been impacted by COVID-19?

Tiziana Life Sciences' stock was trading at $3.95 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, TLSA stock has increased by 8.9% and is now trading at $4.30.
View which stocks have been most impacted by COVID-19
.

Is Tiziana Life Sciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tiziana Life Sciences stock.
View analyst ratings for Tiziana Life Sciences
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Tiziana Life Sciences?

Wall Street analysts have given Tiziana Life Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tiziana Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Doug Parker's approval rating as Tiziana Life Sciences' CEO?

1,448 employees have rated Tiziana Life Sciences CEO Doug Parker on Glassdoor.com. Doug Parker has an approval rating of 60% among Tiziana Life Sciences' employees. This puts Doug Parker in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Tiziana Life Sciences' next earnings date?

Tiziana Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, June 16th 2021.
View our earnings forecast for Tiziana Life Sciences
.

What price target have analysts set for TLSA?

2 Wall Street analysts have issued twelve-month price objectives for Tiziana Life Sciences' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Tiziana Life Sciences' share price to reach $9.50 in the next year. This suggests a possible upside of 120.9% from the stock's current price.
View analysts' price targets for Tiziana Life Sciences
or view Wall Street analyst' top-rated stocks.

Are investors shorting Tiziana Life Sciences?

Tiziana Life Sciences saw a decrease in short interest during the month of December. As of December 31st, there was short interest totaling 330,400 shares, a decrease of 26.8% from the December 15th total of 451,400 shares. Based on an average daily volume of 363,900 shares, the days-to-cover ratio is currently 0.9 days.
View Tiziana Life Sciences' Short Interest
.

Who are some of Tiziana Life Sciences' key competitors?

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA), Enterprise Products Partners (EPD), Novavax (NVAX), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the following people:
  • Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA, Founder & Exec. Chairman (Age 48, Pay $284.56k)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 62, Pay $810k)
  • Dr. Andrea Brancale, Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder
  • Mr. Andrew Westwell Ph.D., Scientific Founder
  • Dr. Yaron Ilan M.D., Chief Medical Officer
  • Dr. Napoleone Ferrara, Chairman of Scientific Advisory Board (Age 63)
  • Prof. Roberto Pellicciari, Consultant

When did Tiziana Life Sciences IPO?

(TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. acted as the underwriter for the IPO.

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA."

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Tiziana Life Sciences' stock price today?

One share of TLSA stock can currently be purchased for approximately $4.30.

How big of a company is Tiziana Life Sciences?

Tiziana Life Sciences has a market capitalization of $276.15 million. The company earns $-9,320,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis. Tiziana Life Sciences employs 8 workers across the globe.

What is Tiziana Life Sciences' official website?

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7495-2379 or via email at [email protected]

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.